Pulmonx Corp Files 8-K on Financials
Ticker: LUNG · Form: 8-K · Filed: Oct 30, 2024 · CIK: 1127537
| Field | Detail |
|---|---|
| Company | Pulmonx Corp (LUNG) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting
TL;DR
Pulmonx filed an 8-K for financial reporting on Oct 30, 2024.
AI Summary
Pulmonx Corporation filed an 8-K on October 30, 2024, to report on its results of operations and financial condition. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event for the company.
Why It Matters
This filing signifies Pulmonx Corporation's adherence to regulatory reporting requirements, providing updates on its financial performance and operational status to investors and the public.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for results of operations and financial condition, with no immediate negative or positive financial disclosures in the provided text.
Key Players & Entities
- Pulmonx Corporation (company) — Registrant
- October 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 700 Chesapeake Drive Redwood City, CA 94063 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Pulmonx Corporation?
The primary purpose of this 8-K filing is to report on Pulmonx Corporation's results of operations and financial condition.
On what date was this 8-K report filed?
This 8-K report was filed on October 30, 2024.
In which state is Pulmonx Corporation incorporated?
Pulmonx Corporation is incorporated in Delaware.
What is the address of Pulmonx Corporation's principal executive offices?
The address of Pulmonx Corporation's principal executive offices is 700 Chesapeake Drive, Redwood City, CA 94063.
Does the provided text contain specific financial figures or operational details?
No, the provided text of the 8-K filing does not contain specific financial figures or detailed operational information; it primarily serves as a notification of the filing's subject matter.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-10-30 16:10:45
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value LUNG The Nasdaq Stock Market
Filing Documents
- lung-20241030.htm (8-K) — 28KB
- lung3q24earningsrelease103.htm (EX-99.1) — 143KB
- pulmonxlogoa.jpg (GRAPHIC) — 8KB
- 0001127537-24-000082.txt ( ) — 314KB
- lung-20241030.xsd (EX-101.SCH) — 2KB
- lung-20241030_lab.xml (EX-101.LAB) — 21KB
- lung-20241030_pre.xml (EX-101.PRE) — 12KB
- lung-20241030_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 30, 2024, Pulmonx Corporation (the "Company") issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2024. A copy of the Company's press release dated October 30, 2024, titled "Pulmonx Reports Third Quarter 2024 Financial Results" is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under "Item 2.02 Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated October 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pulmonx Corporation Dated: October 30, 2024 By: /s/ Mehul Joshi Mehul Joshi Chief Financial Officer